Anti-Human HGFR/c-MET Recombinant Nanobody (SAA1308) (HY196023)

Name: Anti-Human HGFR/c-MET Recombinant Nanobody (SAA1308)
Brand: abinScience
SKU: HY196023
Price: 126 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HY196023

Description

Anti-Human MET/c-Met/HGFR Nanobody (SAA1308) [SAA1308] (HY196023) is a alpaca monoclonal antibody detecting MET in ELISA, FCM. Suitable for Human.

Highlights

●Flow Cytometry — Validated for flow cytometry applications.

Species reactivity

Human

Applications

ELISA, FCM

Host species

Alpaca

Clonality

Monoclonal

Isotype

VHH-8His-Cys-tag

Clone ID

SAA1308

Target

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P08581

Form

Liquid

Storage buffer

0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).

Note

For research use only.

Images